We are live on ! Find out more
TELO icon

Telomir Pharmaceuticals
TELO

39 hedge funds and large institutions have $14.9M invested in Telomir Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

15% more funds holding

Funds holding: 34 → 39 (+5)

13% more capital invested

Capital invested by funds: $13.1M → $14.9M (+$1.77M)

5.09% more ownership

Funds ownership: 6.91% → 12% (+5.1%)

Holders
39
Holders Change
+5
Holders Change %
+14.71%
% of All Funds
0.51%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
26
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$3.25M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$824K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$552K
4
Northern Trust
Northern Trust
Illinois
+$485K
5
State Street
State Street
Massachusetts
+$376K

Top Sellers

Rank Fund Capital Flow
1
LPL Financial
LPL Financial
California
-$64.2K
2
Jones Financial Companies
Jones Financial Companies
Missouri
-$1.23K
3
CPA
Capital Performance Advisors
California
-$141
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$5.23M +$552K +117,227 +10%
BlackRock
2
BlackRock
New York
$4.35M +$3.25M +690,097 +188%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$1.7M +$824K +174,940 +73%
Northern Trust
4
Northern Trust
Illinois
$625K +$485K +102,948 +211%
State Street
5
State Street
Massachusetts
$477K +$376K +79,700 +221%
Bank of New York Mellon
6
Bank of New York Mellon
New York
$298K +$98.6K +20,931 +41%
GAM
7
Gotham Asset Management
New York
$229K +$31.9K +6,770 New
SEM
8
Suncoast Equity Management
Florida
$211K – – –
Goldman Sachs
9
Goldman Sachs
New York
$208K +$238K +50,530 New
Charles Schwab
10
Charles Schwab
California
$191K +$168K +35,556 +328%
JP Morgan Chase
11
JP Morgan Chase
New York
$171K +$179K +37,980 +1,096%
Morgan Stanley
12
Morgan Stanley
New York
$166K +$136K +28,767 +251%
Barclays
13
Barclays
United Kingdom
$123K +$108K +22,941 +327%
T
14
Transce3nd
Texas
$119K +$136K +28,803 New
N
15
Nuveen
North Carolina
$103K +$118K +24,990 New
UBS Group
16
UBS Group
Switzerland
$103K +$99.5K +21,122 +555%
Citigroup
17
Citigroup
New York
$62.8K +$55.4K +11,750 +337%
VF
18
Virtu Financial
New York
$62K +$70.5K +14,959 New
AI
19
Atom Investors
Texas
$61.9K +$70.8K +15,017 New
Bank of America
20
Bank of America
North Carolina
$60.6K +$51.3K +10,880 +284%
BHWM
21
Beaird Harris Wealth Management
Texas
$60.2K – – –
New York State Common Retirement Fund
22
New York State Common Retirement Fund
New York
$48.6K – – –
Mirae Asset Global ETFs Holdings
23
Mirae Asset Global ETFs Holdings
Hong Kong
$44.1K +$37.1K +7,879 +279%
Wells Fargo
24
Wells Fargo
California
$41.4K +$38.9K +8,245 +458%
CF
25
Corebridge Financial
Texas
$39.6K +$33.2K +7,041 +274%
1
2

TELO Hedge Fund Activity: Q4 2024 in Review

39 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Telomir Pharmaceuticals (TELO) for Q4 2024, worth a combined $14.9M — up 13% from $13.1M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new TELO positions and 3 closed out — a net gain of 5 holders — while 26 added to existing stakes and 0 trimmed.

The largest buyer was BlackRock, adding an estimated $3.25M. The largest seller was LPL Financial, exiting entirely with an estimated $64.2K sold.

  • 39 institutional investors held Telomir Pharmaceuticals (TELO) as of Q4 2024, up from 34 in Q3 2024.
  • Funds reported $14.9M of Telomir Pharmaceuticals stock for Q4 2024, up 13% quarter-over-quarter.
  • 8 funds opened new Telomir Pharmaceuticals positions in Q4 2024 and 3 closed out, a net change of +5 holders.
  • The largest Telomir Pharmaceuticals buyer in Q4 2024 was BlackRock, an estimated $3.25M added.
  • The largest Telomir Pharmaceuticals seller in Q4 2024 was LPL Financial, an estimated $64.2K sold.

Based on aggregated 13F filings for Q4 2024.